Europe Plasma Protein Therapeutics Market Size- By End User, By Product Type, By Application- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Description

Europe Plasma Protein Therapeutics Market Introduction and Overview

According to SPER market research, 'Europe Plasma Protein Therapeutics Market Size- By End User, By Product Type, By Application - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Europe Plasma Protein Therapeutics Market is predicted to reach USD 16320.44 million by 2033 with a CAGR of 6.12%.

Plasma protein therapies are a class of pharmaceuticals based on the proteins present in human blood plasma. Blood coagulation, fluid balance, and immune response modulation are just a few of the basic processes for which the body employs these proteins. Immunological deficits, bleeding problems, genetic defects, and other conditions are treated with plasma protein therapies. To guarantee correct dosage and reduce any possible side effects, they must be regularly monitored. Typically, injections or infusions are used to give them.

The early stages of the COVID-19 pandemic had a major effect on the plasma protein therapies sector for a variety of reasons, including a decrease in plasma donors, the closure of labs and testing centers, and restrictions on the import and export of pharmaceuticals. But as the limitations were removed, the company started to grow again. Additional plasma protein therapy product releases and related research initiatives are anticipated to fuel market growth.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By End User, By Product Type, By Application

Regions covered UK, France, Germany, Italy, Spain, Rest of Europe

Companies Covered Abeona Therapeutics Inc., ADMA Biologics Inc., Baxter International Inc., Bayer AG, CSL Limited (CSL Behring), Grifols, S.A., Kedrion S.p.A, Octapharma AG, Taibang Biological Group Co., Ltd, Takeda Pharmaceutical Company Limited, Others.

Europe Plasma Protein Therapeutics Market Segmentation:

By End User: Based on the End User, Europe Plasma Protein Therapeutics Market is segmented as; Hospitals, Others.

By Product Type: Based on the Product Type, Europe Plasma Protein Therapeutics Market is segmented as; Immunoglobulin, Albumin, Plasma derived factor VIII, Other.

By Application: Based on the Application, Europe Plasma Protein Therapeutics Market is segmented as; Idiopathic Thrombocytopenic Purpura, Primary Immunodeficiency Disorder, Others.

Product Code: HLCA2441

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
4.2. COVID-19 Impacts of the Europe Plasma Protein Therapeutics Market

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Europe Plasma Protein Therapeutics Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Europe Plasma Protein Therapeutics Market

7. Europe Plasma Protein Therapeutics Market, By End User (USD Million) 2020-2033

7.1. Europe Plasma Protein Therapeutics Market Size, Share and Forecast, By End User, 2020-2026
7.2. Europe Plasma Protein Therapeutics Market Size, Share and Forecast, By End User, 2027-2033
7.3. Hospitals
7.4. Others

8. Europe Plasma Protein Therapeutics Market, By Product Type (USD Million) 2020-2033

8.1. Europe Plasma Protein Therapeutics Market Size, Share and Forecast, By Product Type, 2020-2026
8.2. Europe Plasma Protein Therapeutics Market Size, Share and Forecast, By Product Type, 2027-2033
8.3. Immunoglobulin
8.4. Albumin
8.5. Plasma derived factor VIII
8.6. Other

9. Europe Plasma Protein Therapeutics Market, By Application (USD Million) 2020-2033

9.1. Europe Plasma Protein Therapeutics Market Size, Share and Forecast, By Application, 2020-2026
9.2. Europe Plasma Protein Therapeutics Market Size, Share and Forecast, By Application, 2027-2033
9.3. Idiopathic Thrombocytopenic Purpura
9.4. Primary Immunodeficiency Disorder
9.5. Others

10. Europe Plasma Protein Therapeutics Market Forecast, 2020-2033 (USD Million)

10.1. Europe Plasma Protein Therapeutics Market Size and Market Share

11. Europe Plasma Protein Therapeutics Market, By Region, 2020-2033 (USD Million)

11.1. Europe Plasma Protein Therapeutics Market Size and Market Share By Region (2020-2026)
11.2. Europe Plasma Protein Therapeutics Market Size and Market Share By Region (2027-2033)
11.3. France
11.4. Germany
11.5. Italy
11.6. United Kingdom
11.7. Rest of Europe

12. Company Profile

12.1. Abeona Therapeutics Inc.
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
12.2. ADMA Biologics Inc.
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
12.3. Baxter International Inc.
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
12.4. Bayer AG
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
12.5. CSL Limited (CSL Behring)
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
12.6. Grifols, S.A.
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
12.7. Kedrion S.p.A
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
12.8. Octapharma AG
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
12.9. Taibang Biological Group Co., Ltd
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
12.10. Takeda Pharmaceutical Company Limited
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
12.11. Others